As a neurologist and specialist palliative care provider for patients with neurological diseases, I am only rarely consulted for patients with multiple sclerosis (MS). A palliative care consult is mainly requested for advance care planning and care transition in acute settings, such as stroke, acute brain injury, and patients with a neurodegenerative disease with comorbidities in the intensive care unit. 1 In other neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis, and Huntington's disease, palliative care is more approachable, mainly driven by a lack of efficient treatment and reduced life expectancy. This differs significantly with MS where the diagnosis is made at a young adult age, when patients are not willing to address choices concerning the end of life, since the reduction of life expectancy in MS is less apparent. 2 The treatment landscape for MS patients has evolved in a spectacular way in the last two decades which will probably have its influence on survival. 3 The standardized mortality rate in MS was significantly higher in the previous decades but is decreasing rapidly. 4 Immunomodulatory and immunosuppressive treatments show a profound effect on handicap and morbidity, with up to 70% of patients treated with current standard high-efficacy protocols meeting the definition of no evidence of disease activity (NEDA-3) at 5 years. 5 The focus of MS care is shifting from symptom management to control and avoidance of disease activity. Expertise of the MS specialist is requested in the fields of immunology and management of complications of highly active immunosuppressive treatment, but the need for palliative care in these patients is very limited.
Another aspect impeding organization of palliative care for patients with MS is a practical one. Estimating when the terminal phase has started is notoriously difficult, especially in MS patients. Planning of palliative care and organization of palliative care facilities depend heavily on correctly identifying patients with a life expectancy of a few months or less. Incorrectly labeled patients block the scarce hospice beds for unacceptably long times or-even worse-die within hours after admission. Funding for home palliative care is limited as well, making correct recognition of the last weeks equally important. MS is a chronic disease, with a secondary slow deterioration over several decades with variety in disease trajectories of over 35 years. 6 Furthermore, patients with MS usually die from other causes than MS. They die from a not well-understood increased rate of ischemic heart disease and pneumonia, similar to the frail elderly. 7 The care for frail elderly at the end of life does rarely require specialist palliative or neurological care and is cared for by primary care physicians. Adding specialist palliative care on top of general palliative care may not be useful for every frail patient. 8 Palliative care specialists are usually not available at the common place of death of MS patients. Since the course of disease is so protracted, they either die in an elderly care facility or unfortunately due to unanticipated complications, such as overwhelming pneumonia, in acute care hospitals. 9
Finally, neurologists already offer palliative care in daily practice. They do not call it as such; they call it "neurology." An outpatient consultation of a patient with an Expanded Disability Status Scale (EDSS) score of 8 is not focused on curing the disease. The disease-modifying drugs tend to be stopped due to unproven efficacy and reimbursement restrictions. But patients are not sent away, and the neurologist is still in charge focusing on symptom control, advanced care planning, place of residence, coping of the care takers, and existential and spiritual aspects. Every observer would agree this is specialist palliative care. The neurologist however will insist it is not, and call it routine neurological care. 10 Systematically adding a specialist palliative care team to the usual multidisciplinary care of advanced MS may be overdone, stretching scarce resources. It can undermine the relationship between patient and neurologist, and may give the primary health care provider and the neurologist the false idea that symptom control is not their responsibility. 7
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In the vast amount of scientific literature on multiple sclerosis (MS), remarkably little has been written about palliative care (PC) in MS. According to the World Health Organization (WHO), PC is an approach that improves the quality of life of patients (adults and children) and their families who are facing problems associated with life-threatening illness. It prevents and relieves suffering through the early identification, correct assessment and treatment of pain, and other problems, whether physical, psychosocial, or spiritual. The WHO estimates that only a small portion of people who need PC are actually receiving it and argues that a major barrier to improving access to PC is lack of training of health professionals. 1 In addition, it is expected that more people will need PC. 2 These issues probably apply to MS as well. With respect to PC, patients with MS have a wish for truthful and competent communication about end-of-life decisions, advanced care planning and wish to hasten death, and several unmet needs regarding PC. [3] [4] [5] [6] However, health professionals in MS often do not feel competent to offer PC. 7-9 Although both issues signal a problem with PC in MS, exact numbers on how often PC is actually needed in MS are lacking. Nevertheless, given the need for PC of at least a certain amount of the patients with MS and the lack of PC competencies in at least a part of the health professionals, the quality of the relationship between the patient and the health professional could be inadvertently reduced in this final and precarious stage of MS.
Therefore, the first issue that needs to be resolved is to whom and when to introduce PC in MS. Vanopdenbosch and Cambron argue that PC should be limited to the terminal phase, that is, the final months of live, 10 whereas Solari and Pucci argue that PC should start much earlier, that is, when questions about tube-feeding or tracheostomy arise. 11 Since patients with MS with severe disability may suffer from several problems for a prolonged period of time and still have a life expectancy that amply exceeds a few months, an earlier start of PC seems justified in these cases. Future research should try to identify factors that help to predict which and when patients with MS are most likely to benefit from PC, because not all, and hopefully a decreasing number of patients will develop problems that need PC.
